Abstract
Retinal vein occlusion (RVO) is associated with hyperhomocysteinaemia and the antiphospholipid syndrome—disorders known to contribute to both arterial and venous thrombosis. In both of these conditions and RVO, platelet activation occurs. Aspirin, not warfarin, is the most effective antithrombotic agent in RVO and, taken together, these observations suggest an important role for platelets in this common ocular thrombotic condition. Platelet glycoprotein Ia/IIa (GpIa/IIa) is an adhesion molecule mediating platelet–collagen interactions and is key to the initiation of thrombosis. Recently, the cellular density of this molecule was shown to be determined by two silent, linked polymorphisms (C807T/G873A) within the GpIa/IIa gene. There is evidence that some of the resulting genotypes are associated with thrombo-embolic disease. This study therefore aimed to establish the prevalence of the GpIa/IIa polymorphisms and the three commonest hereditary thrombophilic disorders (prothrombin gene G20210A (PT) mutation, Factor V Leiden (FVL), and the thermolabile methylene tetrahydrofolate reductase C677T (MTHFR) mutation) in patients with RVO and normal controls. The GpIa/IIa polymorphisms and thrombophilic abnormalities were all identified using the polymerase chain reaction.
Our results show that the frequency of the GpIa/IIa polymorphisms was similar in our normal control population to previously published series. Patients with RVO, however, had only a 10% (4/40) frequency of the lowest risk subtype (CC/GG) compared to 37.5% (15/40) in the control group—P 0.0039. The incidence of the PT, FVL, and MTHFR thrombophilic mutations was not different between the two groups, but interestingly none of the 7/40 RVO cases with a PT, FVL, or MTHFR mutation had the low-risk GpIa/IIa genotype while all but one of the controls did—P<0.05. Thus, 17.5% of RVO patients harboured more than one prothrombotic abnormality. The principal difference between the RVO and control group was the very high incidence of the intermediate-risk GpIa/IIa subtype (CT/GA)—82.5 vs 50%, P<0.05.
These results suggest a major role for GpIa/IIa polymorphisms in the pathogenesis of RVO.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Hayreh SS, Zimmerman MB, Podhajsky P . Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117: 429–441.
Mitchell P, Smith W, Chang A . Prevalence and associations of retinal vein occlusion in Australia. The Blue Eye Mountain Study. Arch Ophthalmol 1996; 114: 1243–1247.
Dodson PM, Galton DJ, Hamilton AM, Blach RK . Retinal vein occlusion and the prevalence of lipoprotein abnormalities. Br J Ophthalmol 1982; 66: 161–164.
Rath EZ, Frank RN, Shin DH, Kim C . Risk factors for retinal vein thrombosis: a case–control study. Ophthalmology 1992; 99: 509–514.
Kirwin JF, Tsaloumas MD, Vinall H, Prior P, Kritzinger EE, Dodson PM . Sex hormone preparations and retinal vein occlusion. Eye 1997; 11: 53–56.
Dodson PM, Kritzinger EE, Clough GC . Diabetes mellitus and retinal vein occlusion in patients of Asian, West Indian and white European origin. Eye 1992; 6: 66–68.
Fegan C . Central retinal vein occlusion and thrombophilia. Eye 2002; 16: 98–106.
Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7–9.
Martin SC, Rauz S, Marr JE, Martin N, Jones AF, Dodson PM . Plasma total homocysteine and retinal vascular disease. Eye 2000; 14: 590–593.
Dodson PM, Westik J, Marks G, Kakkar VV, Galton DJ. β-Thromboglobulin and platelet factor 4 levels in retinal vein occlusion. Br J Ophthalmol 1983; 67: 143–146.
Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged platelet treatment. BMJ 1998; 296: 320–331.
Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A . European Stroke Prevention Study 2. Dypyridamole and acetlysalicylic acid in the prevention of primary stroke. J Neuro Sci 1996; 143: 1–13.
Levine JS, Branch DW, Rauch J . The antiphospholipid syndrome. N Eng J Med 2002; 346: 752–763.
Makris M . Hyperhomocysteinaemia and thrombosis. Clin Lab Haematol 2000; 22: 133–143.
George GN . Platelets. Lancet 2000; 355: 1531–1539.
Kunicki TJ, Kritzik M, Annis DS, Nugent DJ . Hereditary variation in platelet integrin α2β1 density is associated with two silent polymorphisms in the α2 gene coding sequence. Blood 1997; 89: 1939–1943.
Corral J, Gonzalez-Conejero R, Rivera J, Ortuno F, Aparicio P, Vicente V . Role of the 807c/t polymorphism of the α2 gene in platelet GP Ia collagen receptor expression and function. Effect in thromboembolic diseases. Thromb Haemostat 1999; 81: 951–956.
Moshfegh K, Wuillemin WA, Redondo M, Lammle B, Beer JH, Liechti-Gallati S . Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case–control study. Lancet 1999; 353: 351–354.
Santosa S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A . Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999; 93: 2449–2453.
Croft SA, Hampton KK, Sorrell JA, Steeds RP, Channer KS, Samani NJ et al. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol 1999; 106: 771–777.
Carlsson LE, Santosa S, Spitzer C, Kessler C, Greinacher A . The α2 gene coding sequence T807/A873 of the platelet collagen receptor integrin α2β1 might be a genetic risk factor in the development of stroke in younger patients. Blood 1999; 93: 3583–3586.
Hessner MJ, Dinauer DM, Luhm RA, Endres JL, Montgomery RR, Friedman KD . Contribution of the glycoprotein Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691GA (Leiden) carriers. Br J Haematol 1999; 106: 237–239.
Casorelli I, De Stefano V, Leone AM, Chiusolo P, Burzotta F, Paciaroni K et al. The C807T/G873A polymorphism in the glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. Br J Haematol 2001; 114: 150–154.
Matsubara Y, Murata M, Maruyama T, Handa M, Yamagata N, Watanabe G et al. Association between diabetic retinopathy and genetic variations in α2β1 integrin, a platelet receptor for collagen. Blood 2000; 95: 1560–1564.
World Health Organization. Report of a WHO Expert Committee on hypertension. WHO Technical Report Series. WHO: Geneva, 1979.
British Hyperlipidaemic Association. Detection and Management of Blood Lipid Disorders. Science Press: London, 1990.
Gandrille S, Alhenc-Gelas M, A rapid screening method for the factor V arg506-gln mutation. Blood Coag Fibrinol 1995; 6: 245–248.
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM . A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–3703.
Froost P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111–113.
Dinauer DM, Freidman KD, Hessner MJ . Allelic frequency of the glycoprotein Ia (α2 integrin) C807T/G873A dimorphisms among Caucasian venous thrombosis patients and six racial groups. Br J Haematol 1999; 107: 563–565.
Coller BS, Beer JH, Scudder LE, Steinberg MH . Collagen–platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with GPIIb/IIIa mediated by adhesive proteins. Blood 1989; 74: 182–192.
Kirchhofer D, Tschoop TB, Steiner B, Baumgartner HR . Role of collagen-adherent platelets in mediating fibrin formation in flowing whole blood. Blood 1995; 86: 3815–3822.
Olds RJ, Fitches AC, Geary CPM . The multigenic basis for venous thrombosis. Br J Haematol 2000; 109: 508–511.
Fong AC, Schatz H . Central retinal vein occlusion in young adults. Surv Ophthalmol 1993; 37: 393–417.
Dodson PM, Kritzinger EE . Underlying medical conditions in young patients and ethnic differences in retinal vein occlusion. Trans Ophthalmol Soc UK 1985; 104: 114–119.
Vandenbrouke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR . Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453–1457.
Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817–2821.
Gleuk CJ, Wang P, Fontaine RN, Sieve-Smith L, Lang JE . Interaction of estrogen replacement therapy with the thrombophilic 20210G/A prothrombin gene mutation for atherthrombotic vascular disease: a cross sectional study of 275 hyperlipidaemic women. Metabolism 2001; 50: 360–365.
Rees DC, Chapman NH, Webster MT, Guerreiro JF, Rochette J, Clegg JB . Born to clot: the European burden. Br J Haematol 1999; 105: 564–566.
Larsson J, Hillarp A . The prothrombin gene G20210A mutation and the platelet glycoprotein IIIa polymorphism PlA2 in patients with central retinal vein occlusion. Thromb Res 1999; 96: 323–327.
Tsaloumas MD, Kirwan J, Vinall H, O'Leary MB, Prior P, Kritzinger EE et al. Nine year follow up study of morbidity and mortality in retinal vein occlusion. Eye 2000; 14: 821–827.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dodson, P., Haynes, J., Starczynski, J. et al. The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion. Eye 17, 772–777 (2003). https://doi.org/10.1038/sj.eye.6700452
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6700452
Keywords
This article is cited by
-
Genetic polymorphisms associated with the prevalence of retinal vein occlusion in a Greek population
International Ophthalmology (2019)
-
Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: an updated meta-analysis
BMC Ophthalmology (2014)
-
Effects of interacting networks of cardiovascular risk genes on the risk of type 2 diabetes mellitus (the CODAM study)
BMC Medical Genetics (2008)
-
807C/T polymorphism in platelet glycoprotein Ia gene is not associated with retinal vein occlusion
Graefe's Archive for Clinical and Experimental Ophthalmology (2007)
-
The platelet glycoprotein Ia/IIa gene polymorphism C807T/C873A: a novel risk factor for retinal vein occlusion
Eye (2004)
